First AD

Second AD

The EMBARK trial investigating enzalutamide in NM CSPC

Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?

Please comment of the high risk study population evaluated in the EMBARK trial

What were the primary endpoints and efficacy findings from the EMBARK trial? Please also comment on your impressions of the monotherapy arm.

What are your impressions of the safety data from EMBARK?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer. 